Mezzion Announces Re-Submission of New Drug Application for its Orphan Drug Udenafil to Treat Patients who have undergone the Fontan Operation for Single Ventricle Heart Disease ...Middle East

SEOUL, South Korea, March 28, 2021 /PRNewswire/ -- Mezzion Pharma Co. Ltd. (140410.KQ), announced today that it has re-submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the approval of udenafil to improve the exercise capacity of patients 12 years...

Hence then, the article about mezzion announces re submission of new drug application for its orphan drug udenafil to treat patients who have undergone the fontan operation for single ventricle heart disease was published today ( Monday 29/03/2021 - 03:45 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Mezzion Announces Re-Submission of New Drug Application for its Orphan Drug Udenafil to Treat Patients who have undergone the Fontan Operation for Single Ventricle Heart Disease )

Also on site :

• 2000s Heavy Metal Band Shares Exciting Music Festival News
• Saudi to Sudan: Can Pakistan expand military footprint across Arab world?
• Large house fire near Buckeye Lake kills one, critically injures second victim